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Channeling Ions and Hope: Cystic Fibrosis
Foundation Follows Phlegmatic StrategyCystic fibrosis (CF) is a fatal genetic
disease that affects 30,000 children
and adults in the U.S. and another
75,000 in developed countries.
Thus, it is not on the radar of any ma-
jor pharmaceutical company and is
classified as an orphan disease. Pa-
tients affected by CF produce thick
and viscous mucus that cannot be
easily secreted from the body. Since
mucus is an aqueous solution of
both proteins and electrolytes, its
rheological properties are deter-
mined by the balance between
them. Our bodies have evolved so
that the viscosity of mucus is tied
to the function it serves. A disruption
of this fine balance leads not only to
a lack of efficiency, but also to a
deadly disease.
Like the ancient medical concept
of sickness caused by unbalanced
humors, CF is caused by a defect in
the CFTR (cystic fibrosis transmem-
brane conductance regulator) gene,
which encodes a functional chloride
channel that is essential to regulate
transport of electrolytes through the
membranes of epithelial cells that
secrete mucus. These cells line the
lungs, the digestive system, the
male reproductive tract, and other
systems. With an imbalance in ion
flow, CF patients eventually die of
respiratory failure caused by lungde-
generation due to chronic infection
resulting from congested airways.
CF also causes malnutrition and
male infertility.
While malfunctioning of a single
gene product causes CF, there may
be 1500 mutations that can lead to
defective protein, resulting in differ-
ing individual manifestations of the
disease. Today, the life expectancy
of a CF patient is a little over age
36, mainly as a result of the activity
of the Cystic Fibrosis Foundation
(CFF) (www.cf.org), founded in
1955, which supports basic research
and drug discovery. The discovery
of the gene responsible for cystic
fibrosis in 1999 was a direct result
of prior research funded by theCFF. This research brought hope
to patients for fundamental treat-
ment rather than measures that only
hold off the fatal side effects of the
disease.
A Business Model of Risk
Reduction
Six years ago, the CFF jumpstarted
Cystic Fibrosis Foundation Thera-
peutics, Inc. (CFFT), to bring poten-
tial CF drugs to the market faster.
‘‘We have a very aggressive drug dis-
covery program,’’ said Dr. Robert
Beall, president of CFFT and the CFF.
The CFFT commits millions of dol-
lars to research and partners with
companies through its therapeutic
development awards program. The
organization has become the model
for other patient advocacy groups
and the darling of the business com-
munity. ‘‘What is unique is that you
have a foundation that is holding
companies just as accountable as
another pharmaceutical company,’’
said Beall.
Six years ago, the CFF
jumpstarted Cystic Fibro-
sis Foundation Therapeu-
tics, Inc. (CFFT), to bring
potential CF drugs to the
market faster. ‘‘We have
a very aggressive drug
discovery program,’’ said
Dr.RobertBeall, president
of CFFT and the CFF.
Sometimes the CFFT functions as
a lead investor, giving its imprimatur
to a tiny biotech. The CFFT invested
in Boston-based Altus Pharmaceuti-
cals (www.altus.com) to develop
pancreatic enzymes. ‘‘Our . seal
of approval allowed them to get
venture capital money,’’ said Beall.
‘‘They recently went public. We put$25 million dollars in. We got a prod-
uct that will probably go into phase
III soon. They actually got a company
out of it. We enabled that, but the
most important thing is that we got
a product in the end.’’
Reconciling differing agendas is
key to CFFT collaborations with
companies. ‘‘Are they committed to
taking this thing through to the pa-
tients if we help out and reduce the
risk?’’ Beal asked. ‘‘The biggest
risk for us is not taking risk. We
don’t know what is going to work,
but we have to get drugs for our pa-
tients.’’ Collaborations are struc-
tured like biotech deals. ‘‘Most of
the companies own the IP.’’ Beall
said, ‘‘We have royalty rights and
payback projections. If the data
looks good and they don’t want to
develop it, we have the right to reach
in and develop it ourselves.’’
Pipeline of Hope
The CFFT’s pipeline includes basic
research such as gene therapy and
supports novel approaches like the
one that targets the nonsense
mutations affecting 10% of CF pa-
tients, developed by New Jersey-
based PTC Therapeutics, Inc. (www.
ptcbio.com). ‘‘Nonsense’’ mutations
stunt the CFTR protein’s growth so it
cannot develop into the ion channel
for chloride secretion and sodium
absorption. PTC’s lead compound,
PTC124, funded by $1.7 million of
CFFT money, is now enrolling Phase
II trials and has fast track and or-
phan drug status.
‘‘That pipeline is the most impor-
tant metric that we have for our
own performance for this organiza-
tion,’’ said Beall. ‘‘This is an impor-
tant metric for the parents. This is
a metric of hope.’’
Balancing Humors
Developing an orphan drug can
launch a company, especially when
it provides a platform that can be ex-
tended to other therapies in larger
markets. The mucus management
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558business has been good to North
Carolina-based Inspire Pharma-
ceuticals (www.inspirepharm.com),
getting the company publicly traded
on NASDAQ. Inspire’s business
model is to license intellectual prop-
erty from universities and outsource
the labor-intensive screening and
manufacturing.
Inspire’s CF candidate, INS-37217
or denufosol tetrasodium, a selec-
tive P2Y2 receptor agonist, has
been granted FDA fast track and or-
phan drug status. The P2Y2 receptor
is a protein expressed on the sur-
face of cells that binds ligands to ac-
tivate an alternative chloride chan-
nel that bypasses the defective
one. The alternative path enables
better secretion of electrolytes and
fluid through the cell membrane
and accelerates the beating fre-
quency of the cilia that clear lung
linings of mucus.
Dr. Michael Knowles, professor of
medicine at the University of North
Carolina at Chapel Hill and an Inspire
founder, discovered the P2Y2 recep-
tor while studying the relationship
between electrolyte secretion and
lung disease at UNC 25 years ago.
‘‘We had the notion that defects in
salt and water metabolism in the air-
ways were a part of human disease
and it turns out that we later found
out that cystic fibrosis was the genetic
experiment of nature that proved our
hypothesis. that it is important to
hydrate or regulate the secretions in
the airways,’’ said Knowles. It has
taken ten years for denufosol to go
fromconcept toPhaseIII study. ‘‘There
is no doubt that the CF Foundation
has been helpful’’ said Knowles.
Denufosol, administered by inha-
lation, is meant for the two-thirds
of CF patients with early or mild
lung disease. ‘‘We are positioning
the drug for a potential indication in
early intervention,’’ said Dr. M.
Lynn Smiley, chief medical officer
at Inspire, ‘‘There are a lot of analo-
gies to treating asymptomatic HIV
infection, in hopes that if we catch
these patients in more of an earlier
subclinical stage, that we can make
a bigger impact and that they can
live even longer and maintain
healthy airways. Once they start los-
ing certain airways, there is no re-
versibility to it.’’
Inspire plans to conduct two clin-
ical trials this year. The company
has already conducted six studieswith 300 patients and volunteers.
The company has since expanded
its P2Y2 receptor platform to other
treatments correcting imbalances
of fluids in the areas of allergies,
eye disease, and respiratory thera-
pies, as well as a reversible treat-
ment for platelet aggregation for
heart disease. Inspire currently has
two eye dysfunction products on
the market with their partner Aller-
gan: Elestat and Restasis.
‘‘We did some of the basic work
when it [the P2Y2 receptor] was still
at UNC,’’ recalls Bob Beall, ‘‘We ac-
tually paid the University of North
Carolina to patent the product.
They already licensed it off to In-
spire. They actually found an indica-
tion for dry eye and so they went off
on that tangent. A couple of years
ago we got really impatient and
said we will pay for the next stage,
the Phase I, Phase II clinical trials.
They did it and got positive data.
Now the board is behind it. It is mov-
ing to end of Phase III trials next
month. We prodded them and paid
them. It would not have been done
without us. They used our clinical
trials network.’’
Stepping Up Channel Activity
Another promising therapy comes
from Cambridge, MA, based Vertex
Pharmaceuticals, Inc. (www.
vpharm.com). The FDA recently
awarded fast track status for VX-
770, Vertex’s potentiator molecule
that increases the gating activity of
the CFTR chloride channel to im-
prove ion transport. VX-770 is cur-
rently in Phase I development. Ac-
cording to Eric Olson, program
director for Vertex, the company is
also working on molecules known
as correctors, which are designed
to alleviate the effects of the traffick-
ing defect of DF508 CFTR, the mu-
tant protein found in most CF pa-
tients that doesn’t efficiently travel
to the cell surface.
Vertex has been working on the
two approaches in parallel since
2000. They were originated by San
Diego-based Aurora Biosciences,
which was purchased by Vertex in
2001. The CFFT has invested about
$21 million in the Vertex collabora-
tion so far through the end of 2007.
Help from Australian Surfers
Currently CF patients are treated
with physical therapy, mucus-thin-ning drugs like Pulmozyme, the
antibiotics TOBI (tobramycin for in-
halation) and azithromycin, and pan-
creatic enzyme supplements to alle-
viate nutritional deficiencies.
Most patients are diagnosed at
between 6 months and 2 years of
age. ‘‘The strategy is to diagnose
kids and get them into preventative
treatment as soon as possible.’’
says Dr. Preston W. Campbell, III,
executive vice president for medical
affairs at the Cystic Fibrosis Foun-
dation. If they can stave off infec-
tions and keep them from becoming
entrenched at an early age, the on-
set of irreversible lung damage is
delayed. ‘‘Once infection is estab-
lished, it sticks for life,’’ said Camp-
bell. ‘‘Their airways will be colonized
with pseudomonas. Early on, that
infection can be eradicated.’’
One promising therapy—adminis-
tering hypertonic saline solution to
the lungs—is actually low tech. It
was developed after Australian
surfers with CF noticed that their
lungs felt considerably better after
a day riding the waves. The treat-
ment involves inhalation of a con-
centrated saltwater mist for a few
hours a day. The hypertonic saline
program has undergone Phase III
trials and is being tried out on youn-
ger children.
The CFF coordinates 117 different
patient care centers around the
country as well as 91 adult programs
and 51 affiliated programs at hospi-
tals and teaching centers. The CFF
supplements this with a data registry
that follows about 23,000 patients.
‘‘We are interested in refining best
practices.’’ Campbell said. ‘‘Those
clinical outcomes will help us to re-
duce variability in treatment of pa-
tients.’’ This patient information and
feedback enables the CFFT to effi-
ciently coordinate further research
and development for CF therapies.
‘‘Right now, patients with CF in
general experience a 2% decline in
lung function [a year]’’ said Camp-
bell, ‘‘If we can reduce the 2% to
1%, then we can extend median sur-
vival to late sixties. We buy time for
the cures we are focused on.’’
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